Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)
Start Date
9/16/2026
Completion Date
2/1/2028
Summary
This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infusion. For patients interested in additional information on how to participate, please follow this link: https://mytomorro.ws/ph1trial.
Eligibility Criteria
Age Range: 6 years to No maximum
Interventions
YOLT-203
Placebo
Conditions
Locations
University of Alabama at Birmingham (UAB Hospital)
Birmingham, Alabama 35249
United States
Childrens Hospital of Colorado
Aurora, Colorado 80045
United States
Washington University/Barnes Jewish Hospital
St Louis, Missouri 63108
United States
University of Pennsylvania Health System (UPHS) - Penn Medicine
Philadelphia, Pennsylvania 19107
United States